Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers
Authors
Yuichiro Ueda
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Hiroki Ishii
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Taisuke Kitano
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Mitsutoshi Shindo
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Haruhisa Miyazawa
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Kiyonori Ito
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Keiji Hirai
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Yoshio Kaku
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Honami Mori
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Taro Hoshino
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Susumu Ookawara
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
Masafumi Kakei
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medial University, Saitama, Japan.
linagliptin, diabetic nephropathy, renin–angiotensin–aldosterone system blockers, glucose and lipid metabolism, renal function
Abstract
BACKGROUND:
We investigated the effects and safety of linagliptin as an add-on therapy in patients with advanced-stage diabetic nephropathy (DMN) taking renin–angiotensin–aldosterone system (RAAS) blockers.
METHOD:
Twenty advanced-stage DMN patients (estimated glomerular filtration rate (eGFR): 24.5 ± 13.4 mL/min/1.73 m2) taking RAAS blockers were administered 5 mg/day linagliptin for 52 weeks. Changes in glucose and lipid metabolism and renal function were evaluated.
RESULTS:
Linagliptin decreased glycosylated hemoglobin levels (from 7.32 ± 0.77% to 6.85 ± 0.87%, P , 0.05) without changing fasting blood glucose levels, and significantly decreased total cholesterol levels (from 189.6 ± 49.0 to 170.2 ± 39.2 mg/dL, P , 0.05) and low-density lipoprotein cholesterol levels (from 107.1 ± 32.4 to 90.2 ± 31.0 mg/dL, P , 0.05) without changing high-density lipoprotein cholesterol and triglyceride levels. Urine protein/creatinine ratio and annual change in eGFR remained unchanged. No adverse effects were observed.
CONCLUSION:
Linagliptin as an add-on therapy had beneficial effects on glucose and lipid metabolism without impairment of renal function, and did not have any adverse effects in this population of patients with advanced-stage DMN taking RAAS blockers.
Ueda, Y., Ishii, H., Kitano, T., Shindo, M., Miyazawa, H., Ito, K., Hirai, K., Kaku, Y., Mori, H., Hoshino, T., Ookawara, S., Kakei, M., Tabei, K., & Morishita, Y. (2016). Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers. Drug Target Insights, 10(1). https://doi.org/10.33393/dti.2016.1422